Literature DB >> 28490592

Epstein-Barr Virus Rta-Mediated Accumulation of DNA Methylation Interferes with CTCF Binding in both Host and Viral Genomes.

Yen-Ju Chen1, Yu-Lian Chen1, Yao Chang2, Chung-Chun Wu1, Ying-Chieh Ko1, Sai Wah Tsao3, Jen-Yang Chen4, Su-Fang Lin4.   

Abstract

Rta, an Epstein-Barr virus (EBV) immediate-early protein, reactivates viral lytic replication that is closely associated with tumorigenesis. In previous studies, we demonstrated that in epithelial cells Rta efficiently induced cellular senescence, which is an irreversible G1 arrest likely to provide a favorable environment for productive replications of EBV and Kaposi's sarcoma-associated herpesvirus (KSHV). To restrict progression of the cell cycle, Rta simultaneously upregulates CDK inhibitors and downregulates MYC, CCND1, and JUN, among others. Rta has long been known as a potent transcriptional activator, thus its role in gene repression is unexpected. In silico analysis revealed that the promoter regions of MYC, CCND1, and JUN are common in (i) the presence of CpG islands, (ii) strong chromatin immunoprecipitation (ChIP) signals of CCCTC-binding factor (CTCF), and (iii) having at least one Rta binding site. By combining ChIP assays and DNA methylation analysis, here we provide evidence showing that Rta binding accumulated CpG methylation and decreased CTCF occupancy in the regulatory regions of MYC, CCND1, and JUN, which were associated with downregulated gene expression. Stable residence of CTCF in the viral latency and reactivation control regions is a hallmark of viral latency. Here, we observed that Rta-mediated decreased binding of CTCF in the viral genome is concurrent with virus reactivation. Via interfering with CTCF binding, in the host genome Rta can function as a transcriptional repressor for gene silencing, while in the viral genome Rta acts as an activator for lytic gene loci by removing a topological constraint established by CTCF.IMPORTANCE CTCF is a multifunctional protein that variously participates in gene expression and higher-order chromatin structure of the cellular and viral genomes. In certain loci of the genome, CTCF occupancy and DNA methylation are mutually exclusive. Here, we demonstrate that the Epstein-Barr virus (EBV) immediate-early protein, Rta, known to be a transcriptional activator, can also function as a transcriptional repressor. Via enriching CpG methylation and decreasing CTCF reloading, Rta binding efficiently shut down the expression of MYC, CCND1, and JUN, thus impeding cell cycle progression. Rta-mediated disruption of CTCF binding was also detected in the latency/reactivation control regions of the EBV genome, and this in turn led to viral lytic cycle progression. As emerging evidence indicates that a methylated EBV genome is a preferable substrate for EBV Zta, the other immediate-early protein, our results suggest a mechanistic link in understanding the molecular processes of viral latent-lytic switch.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  CTCF; DNA methylation; Epstein-Barr virus; cell cycle arrest; genome topology; immediate-early protein Rta; lytic cycle reactivation

Mesh:

Substances:

Year:  2017        PMID: 28490592      PMCID: PMC5512236          DOI: 10.1128/JVI.00736-17

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  83 in total

1.  Epstein-Barr virus infection alters cellular signal cascades in human nasopharyngeal epithelial cells.

Authors:  Angela Kwok Fung Lo; Kwok Wai Lo; Sai Wah Tsao; Hing Lok Wong; Jan Wai Ying Hui; Ka Fai To; Diane S Hayward; Yiu Loon Chui; Yu Lung Lau; Kenzo Takada; Dolly P Huang
Journal:  Neoplasia       Date:  2006-03       Impact factor: 5.715

2.  AP-1 homolog BZLF1 of Epstein-Barr virus has two essential functions dependent on the epigenetic state of the viral genome.

Authors:  Markus Kalla; Anne Schmeinck; Martin Bergbauer; Dagmar Pich; Wolfgang Hammerschmidt
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 11.205

3.  Genome-wide analysis of Epstein-Barr virus Rta DNA binding.

Authors:  Andreas M F Heilmann; Michael A Calderwood; Daniel Portal; Yong Lu; Eric Johannsen
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

4.  Activators of the Epstein-Barr virus lytic program concomitantly induce apoptosis, but lytic gene expression protects from cell death.

Authors:  G J Inman; U K Binné; G A Parker; P J Farrell; M J Allday
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

5.  Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism.

Authors:  S Zalani; E Holley-Guthrie; S Kenney
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-20       Impact factor: 11.205

6.  The EBV Latent Antigen 3C Inhibits Apoptosis through Targeted Regulation of Interferon Regulatory Factors 4 and 8.

Authors:  Shuvomoy Banerjee; Jie Lu; Qiliang Cai; Abhik Saha; Hem Chandra Jha; Richard Kuo Dzeng; Erle S Robertson
Journal:  PLoS Pathog       Date:  2013-05-02       Impact factor: 6.823

7.  CpG-methylation regulates a class of Epstein-Barr virus promoters.

Authors:  Martin Bergbauer; Markus Kalla; Anne Schmeinck; Christine Göbel; Ulrich Rothbauer; Sebastian Eck; Anna Benet-Pagès; Tim M Strom; Wolfgang Hammerschmidt
Journal:  PLoS Pathog       Date:  2010-09-23       Impact factor: 6.823

8.  Epstein-Barr virus nuclear antigen 3C facilitates G1-S transition by stabilizing and enhancing the function of cyclin D1.

Authors:  Abhik Saha; Sabyasachi Halder; Santosh K Upadhyay; Jie Lu; Pankaj Kumar; Masanao Murakami; Qiliang Cai; Erle S Robertson
Journal:  PLoS Pathog       Date:  2011-02-10       Impact factor: 6.823

9.  EBV latency types adopt alternative chromatin conformations.

Authors:  Italo Tempera; Michael Klichinsky; Paul M Lieberman
Journal:  PLoS Pathog       Date:  2011-07-28       Impact factor: 6.823

10.  Sustained elevation of Epstein-Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma.

Authors:  M F Ji; D K Wang; Y L Yu; Y Q Guo; J S Liang; W M Cheng; Y S Zong; K H Chan; S P Ng; W I Wei; D T T Chua; J S T Sham; M H Ng
Journal:  Br J Cancer       Date:  2007-02-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.